Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions. Deal Watch is supported by deal intelligence from Strategic Transactions.
Deal Watch: Inventiva Expands Collaborations With Boehringer, AbbVie
French biotech expands fibrosis partnership with Boehringer Ingelheim, and a co-development pact with AbbVie around ROR gamma inverse agonists. Helsinn signs on to detail Novartis' Zykadia in the US.
More from Deals
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
Several biotech execs said they don’t expect much impact from the Trump administration’s threatened tariffs but are reviewing business practices to prepare.
• By
The biopharma sector made acquisitions with total potential value of $33.6bn during Q1, up substantially from the $9.5bn of Q4 2024, according to data from Evaluate.
More from Business
• By
The company discontinued development of its oral GLP-1 receptor agonist for weight management due to a safety signal.
• By
The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.
• By
In this week's episode: Trump’s tariff rollercoaster; regulatory, economic uncertainties hang over Q1 earnings; IPOs rise in Q1 but may slow; Chinese deal-making matures; and AstraZeneca talks about Chinese innovation.